# Elucidating the Role of Endothelial NAD Metabolism in Atherosclerosis

> **NIH NIH F31** · UNIVERSITY OF PENNSYLVANIA · 2021 · $46,036

## Abstract

Project Summary
Atherosclerosis remains a leading cause of death in the United States, even in the context of aggressive clinical
and public health efforts to lower risk factors such as hyperlipidemia. Thus, there is a significant need for better
mechanistic understanding of atherosclerosis pathogenesis in order to develop novel therapeutic strategies
downstream of circulating risk factors. Atherosclerosis pathogenesis begins in the endothelial layer of the arterial
wall: endothelial cell dysfunction (ECD) and EC inflammation precede atherosclerotic plaque formation and are
associated with adverse cardiovascular events. Both ECD and EC inflammation increase with age, and age is a
major non-modifiable risk factor for atherosclerosis. Importantly, activation of sirtuin (SIRT) family of nicotinamide
adenine dinucleotide (NAD+) - dependent deacetylases, particularly SIRT1, has been reported to slow a variety
of age-associated phenotypes. In particular, our lab and others have shown that levels of endothelial NAD+
decrease with age, and that endothelial-specific overexpression of SIRT1 is sufficient to slow ECD and
progression of atherosclerosis. Furthermore, oral administration of NAD+ precursors in aged mice increases
aortic SIRT1 expression and activity, and reduces ECD, suggesting that increasing NAD+ availability can promote
SIRT1 activity in aged ECs. Loss of NAD+ balance thus appears to be central to atherogenesis, but little is known
about how ECs maintain NAD homeostasis. Quantitative flux analysis of NAD+ precursors in live mice has
recently uncovered that liver-derived nicotinamide (NAM) is the main circulating NAD+ precursor that reaches
tissues. This suggests that the enzyme NAM phosphoribosyltransferase (NAMPT), which catalyzes the first and
rate-limiting step in NAD+ synthesis from NAM, is critical for producing endothelial NAD+ and maintaining the
activity of NAD+ - dependent enzymes. Thus, I hypothesize that endothelial NAMPT is cell-autonomously
required to produce NAD+ and maintain endothelial SIRT1 activity, and that endothelial NAMPT
overexpression will protect against progression of atherosclerosis. To test this hypothesis, we have
generated endothelial-specific gain-of-function (GOF) and loss-of-function (LOF) NAMPT mouse models. In Aim
1, I will use cultured primary arterial ECs and stable isotope carbon tracing coupled with quantitative flux analysis
to calculate rates of NAMPT NAD+ production and SIRT1 NAD+ consumption. I will also determine if NAMPT
activity is required for SIRT1 deacetylation activity, and if NAMPT activation is sufficient to maintain SIRT1 activity
upon oxidative stress. In Aim 2, I will test if NAMPT GOF or oral NAD+ supplementation is sufficient to slow
progression of atherosclerosis, and if NAMPT LOF accelerates atherosclerosis. Ultimately, this work will improve
understanding of EC NAD+ metabolism and its role in maintaining SIRT1 activity, and inform if NAMPT activation
and/or NAD+ replenishment could...

## Key facts

- **NIH application ID:** 10231989
- **Project number:** 1F31HL158152-01
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** Ioana Soaita
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $46,036
- **Award type:** 1
- **Project period:** 2021-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10231989

## Citation

> US National Institutes of Health, RePORTER application 10231989, Elucidating the Role of Endothelial NAD Metabolism in Atherosclerosis (1F31HL158152-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10231989. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*